Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

96.19USD
4:00pm EDT
Change (% chg)

$-1.51 (-1.55%)
Prev Close
$97.70
Open
$97.55
Day's High
$98.68
Day's Low
$95.76
Volume
243,681
Avg. Vol
370,805
52-wk High
$153.80
52-wk Low
$49.20

Select another date:

Tue, Apr 3 2018

BRIEF-Alnylam Pharma Co, Agilent Technologies Entered Manufacturing Services Agreement Providing For Supply Of Patisiran Drug Substance By Agilent

* CO, AGILENT TECHNOLOGIES ENTERED MANUFACTURING SERVICES AGREEMENT PROVIDING FOR SUPPLY OF PATISIRAN DRUG SUBSTANCE BY AGILENT

BRIEF-Silence Therapeutics Brings Patent Infringement Proceedings Against Alnylam's Patisiran Product

* SAYS BROUGHT PATENT INFRINGEMENT PROCEEDINGS IN PORTUGAL AGAINST ALNYLAM'S PATISIRAN PRODUCT Source text for Eikon: Further company coverage:

UPDATE 2-Pfizer's rare heart disease drug succeeds in late-stage study

* Brokerage Suntrust estimates sales of $130 mln of drug in 2022

BRIEF-Alnylam Receives European Medicines Agency Prime Designation For Accelerated Assessment Of Lumasiran

* ALNYLAM RECEIVES EUROPEAN MEDICINES AGENCY PRIME DESIGNATION FOR ACCELERATED ASSESSMENT OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)

BRIEF-Regeneron, Alnylam Pharmaceuticals Announce Collaboration To Discover New Treatments For Nonalcoholic Steatohepatitis

* REGENERON AND ALNYLAM PHARMACEUTICALS ANNOUNCE COLLABORATION TO DISCOVER NEW TREATMENTS FOR NONALCOHOLIC STEATOHEPATITIS (NASH)

BRIEF-Alnylam Retains Global Rights To Lumasiran, Investigational RNAi Therapeutic For Treatment Of Primary Hyperoxaluria Type 1

* ALNYLAM RETAINS GLOBAL RIGHTS TO LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)

BRIEF-Alnylam Pharmaceuticals Q4 Non-Gaap Loss Per Share $1.20

* ALNYLAM PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY

BRIEF-FDA Granted Alnylam's Request For Priority Review

* ALNYLAM ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) AND PRIORITY REVIEW STATUS FOR PATISIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS

BRIEF-Alnylam Announces EMA Acceptance Of Marketing Authorisation Application For Patisiran

* ALNYLAM ANNOUNCES EMA ACCEPTANCE OF MARKETING AUTHORISATION APPLICATION (MAA) FOR PATISIRAN FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS

BRIEF-Sanofi And Alnylam Pharmaceuticals Enter Into Partnership

* AND ALNYLAM, ANNOUNCED ON SUNDAY STRATEGIC RESTRUCTURING OF RNAI THERAPEUTICS RARE DISEASE ALLIANCE

Select another date: